Is Liver Biopsy a Gold or an Old Standard in NAFL and NASH?

Examining liver biopsy as a benchmark test in NASH/NAFL trials

May 20, 2020
Rafal Ziecina, MD, PhD | Scott Beasley

In this International Biopharmaceutical Industry article, Scott Beasley and Rafal Ziecina M.D., Ph.D., discuss how non-invasive imaging is replacing liver biopsy as the gold standard for evaluation of fibrosis in non-alcoholic fatty liver disease (NAFLD) and NASH for clinical trials.

Your form has been successfully submitted! Click the button below to access.
VIEW PDF
Rafal Ziecina, MD, PhD
MEET THE AUTHOR

Rafal Ziecina, MD, PhD

Executive Director, Scientific Solutions, Cardiovascular, Endocrine & Metabolic
LEARN MORE
Scott Beasley
MEET THE AUTHOR

Scott Beasley

Executive Director, Project Management, NASH
LEARN MORE